AbbVie says elagolix meets Phase III endpoints in endometriosis

10 February 2016

US drugmaker AbbVie (NYSE: ABBV), in cooperation with Neurocrine Biosciences (Nasdaq: NBIX), announced positive top-line results from the second of two replicate pivotal Phase III clinical trials evaluating the efficacy and safety of elagolix in premenopausal women who suffer pain from endometriosis.

Rights to the orally administered gonadotropin-releasing hormone (GnRH) antagonist were acquired by Abbott (of which AbbVie is a spin-out) from Neurocrine in 2010, under a deal which could earn the latter as much as $575 million (The Pharma Letter June 17, 2010). Neurocrine’s shares were up 3.6% at $32.19 in pre-market trading, and rose 8.7% to $35.00 by mid-afternoon, while AbbVie’s stock was largely unchanged.

Analysts, including Deutsche Bank’s Robyn Karnauskas, have previously forecast peak sales of elagolix at a potential $1.2 billion-plus.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK